An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Shows Promise in Phase 3 Trial On April 28, Boehringer Ingelheim announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoints using both the efficacy and treatment-regimen estimands.
Adults living with obesity or overweight, without type 2 diabetes, who were treated with survodutide experienced sustained weight loss of up to an average of 16.6% after 76 weeks using the efficacy estimand, a statistically significant decrease versus 3.2% in the placebo arm (p . This level of weight loss supports survodutide’s potential as a clinically meaningful treatment option for people living with obesity or overweight.
1 Full data from the Phase III trial will be presented at the upcoming American Diabetes Association’s (ADA) 2026 Scientific Sessions in June.
Endocrine News published a clinical update in Research Highlights on 01 May 2026.
The item focuses on Pharma Friday – May 1, 2026.
Review the original article for the full source wording and details.